For what it's worth, my opinion is that any BP that buys RVX will need to have three things: 1. An existing interest in genetics (e.g., gene therapy, gene editing). 2. A presence in the fields of diabetes, kidney disease, and cardiovascular disease. 3. The pockets to fund whatever it is the FDA is recommending to push RVX-208 over the line. There must be several out there.